APG is establishing a pharmaceutical packaging and logistics hub in Northern Greece — combining serialization, cold-chain handling and multi-modal distribution in a single, regulation-ready gateway into Central and Eastern Europe.
A convergence of trade policy, infrastructure investment and regulatory change is opening a rare window for a purpose-built pharmaceutical gateway in Southern Europe.
The India–Middle East–Europe Economic Corridor positions the Eastern Mediterranean as the key link for Indo-Pacific pharmaceutical trade flows.
Revised EU directives are tightening serialization, packaging and batch release rules — making a single, pre-compliant EU hub more valuable than ever.
Billions in CEF II, EIB and RRF funding are upgrading the North-South rail/road corridor through Greece and the Balkans — APG sits at its Mediterranean terminus.
Connects maritime flows from India and the Gulf to the Eastern Mediterranean, with onward rail and road into Central and Eastern Europe.
One shared, compliant platform to package, prepare and dispatch products into multiple EU markets — no need for multiple local structures.
Packaging, serialization and batch release structured from day one around EU market entry requirements — so your product arrives shelf-ready, not subject to re-work or re-testing.
IMEC, the Vertical Corridor and deeper EU–India ties create a timely opportunity for a new pharmaceutical gateway focused on speed and resilience.
From bulk import to country-ready packs — one integrated platform, one point of regulatory accountability.
Market-ready packaging under EU GMP, including country-specific labeling, leaflet management and late-stage customization for every target market.
EU GMPEU and UK FMD-compliant serialization and aggregation up to pallet level, supporting full traceability and pack integrity from manufacturer to patient.
EU FMD CompliantTemperature-controlled storage (2–8°C for biosimilars and biologics), bonded and non-bonded warehousing for high-value, time-sensitive medicines.
2–8°C ControlledRail and road dispatch through Northern Greece into Bulgaria, Romania, Ukraine and neighboring markets — with real-time tracking and flexible multi-drop capability.
Multi-ModalBatch release under Qualified Person supervision, ensuring full regulatory compliance for EU market entry. Dynamic batch redirection reduces inventory rigidity.
QP SupervisionEnd-to-end optimization of pharma supply chains, GDP compliance design, cold chain lane qualification and facility planning — APG as your knowledge partner.
GDP / GMP AdvisoryAPG’s facility converts bulk pharmaceuticals into commercial-ready, market-specific packs — engineered for throughput, traceability and audit-readiness from the ground up.
Dedicated 2–8°C and ambient zones with continuous monitoring for biosimilars and standard products.
GMP-aligned packaging lines with version-controlled labeling, leaflet management and audit trails.
Full track-and-trace from unit pack to pallet, with direct EMVO connection and data integrity controls.
Zoned facility with restricted access, documented material flows and segregation protocols aligned to GMP requirements.
Qualified Person sign-off for each batch, with batch documentation review and release for EU market distribution.
Customs-bonded capacity for duty-deferred stock, enabling flexible release into multiple EU markets from a single inventory pool.
Pharmaceutical logistics is time-critical. APG’s position at the Aegean gateway delivers a structural speed advantage over congested northern European ports — based on published port transit data and road/rail schedules on the Vertical Corridor.
Rotterdam, Hamburg, Antwerp — longer transit, higher congestion risk, greater inventory exposure
Faster replenishment · lower working capital · greater commercial agility
*vs. Rotterdam/Hamburg transhipment to Sofia, based on published port & rail transit data
Delivery to Central & Eastern Europe in 6–36 hours with flexible multi-drop distribution and real-time GPS tracking. Ideal for urgent and temperature-sensitive shipments.
Ideal for large or temperature-sensitive volumes — stable, cost-efficient and seamlessly integrated into multimodal flows along the Vertical Corridor to Central Europe.
The Vertical Corridor links the Aegean Sea to Central Europe and Ukraine via road and rail, backed by billions in EU funding. APG sits at its southern anchor — the first compliant pharma facility on this critical route.
Connecting the ports of Northern Greece (Thessaloniki, Kavala, Alexandroupolis) with Bulgarian Black Sea ports (Burgas, Varna) and the Danube (Ruse).
Connecting Constanța (Romania) with Gdańsk (Poland), passing through Hungary and Slovakia — the main north-south freight artery of Eastern Europe.
Extending from Lithuania (Klaipėda) to Greece (Thessaloniki) via the Egnatia Odos vertical axes — enabling seamless truck distribution across nine countries.
Since 2022, the Vertical Corridor carries the majority of Ukrainian exports and imports, significantly accelerating EU funding and permitting across all projects.
APG is designed for organizations that need faster, structured access to European pharmaceutical markets without building their own infrastructure in every country.
Companies seeking faster, structured EU access without building their own packaging and logistics footprint in every target market. Ideal for Indian, Gulf and Asian manufacturers entering the EU.
Organizations needing a compliant supply node that supports multi-country packaging and distribution requirements across CEE — from a single, auditable platform.
Carriers, operators and freight forwarders aligned with a strategic pharmaceutical corridor into the European hinterland — seeking a reliable, regulated hub partner.
Parties interested in a platform at the intersection of pharmaceutical compliance, infrastructure and EU-facing trade growth — at an inflection point in global supply chain architecture.
*vs. Rotterdam/Hamburg transhipment to Sofia — based on published port transit data and Vertical Corridor road/rail schedules.
Whether you are a pharma manufacturer seeking EU market access, a logistics partner, or an investor — we are open to structured conversations. Our detailed Business Plan and technical specifications are available under NDA to qualified partners and investors.
Tell us briefly who you are and what you are looking for. We will follow up within 2 business days.
Corporate Name: AIGIS FARMAKEFTIKOS KOMVOS P.C.
Commercial Title: APG — AEGIS Pharma Gateway
Legal Form: Private Company (IKE), operating under the laws of the Hellenic Republic
GEMI No.: 192327203000
VAT No.: EL 803217190
Tax Office: KEFODE Attikis
Registered Address: Konitsis 25, 15125 Maroussi, Greece
Legal Representative: Raphael Diogenis Pantazis, Managing Director
AEGIS Pharma Gateway (APG) is currently in its development and pre-licensing phase. The company does not yet hold pharmaceutical manufacturing, packaging, or distribution authorizations. All references to operational capabilities represent targets contingent on facility completion, equipment validation, and formal licensing by competent authorities (EOF / EMA).
Content on this platform is for general informational purposes only. It does not constitute a formal investment prospectus, solicitation, or public offer. All forward-looking statements are indicative forecasts. Actual results may differ materially. AEGIS Pharma Gateway IKE, its founders, and directors accept no liability for decisions made based on this information.
All content and designs are the exclusive intellectual property of AEGIS Pharma Gateway® (Hellenic IPO, Reg. 8928/2026). Personal data processed in accordance with GDPR (EU) 2016/679 and Greek Law 4624/2019. Governing law: Hellenic Republic. Jurisdiction: Courts of Athens, Greece.